Abstract:Insulin receptors are present on cells throughout the body. Dysregulation of insulin signaling in the brain has been implicated in mood, cognitive disorders, and pathogenesis of Alzheimer’s disease (AD). However, the brain is composed of multiple cells types, and little is known as to how brain insulin resistance in particular in different brain cell types contributes to the comorbidity of type 2 diabetes (T2D) and AD. In this regard, microglia are particularly interesting, since microglia are involved in the uptake and clearance of amyloid-β (Aβ) and formation of neuroinflammation. To investigate the role of insulin signaling in microglial function and development of AD, we have created an inducible microglia-specific insulin receptor knockout (MG-IRKO) and found that loss of microglial insulin signaling in these mice results in alterations in mood, social behavior and impairment in systemic metabolism. At a molecular level, utilizing RiboTag to isolate and profile microglial-specific ribosome-bounded mRNA, we found that loss of insulin receptor resulted in alterations in pathways associated with innate immunity and cellular metabolism in microglia. In vitro, loss of insulin signaling in microglial resulted in metabolic reprograming with a switch to more glycolytic metabolism, and this was associated with impaired ability of microglia in Aβ uptake. When the MG-IRKO mice were crossed with an AD mouse model (5xFAD mice) to create MGIRKO/5xFAD mice, the resultant mice exhibit increased levels of Aβ plaque formation and elevated neuroinflammation marked by increased IFN-γ. Thus, insulin signaling in microglia plays a key role in microglial cellular metabolism, neuroinflammation and the ability of the cells to uptake Aβ, such that loss of insulin signaling in microglia accelerates AD pathogenesis. Together, these data indicate the potential importance of targeting insulin signaling in microglia in treatment of AD. Disclosure W. Chen: None. V.R. Muñoz: None. C. Kahn: Consultant; Cellarity. Other Relationship; 1825 Therapeutics. Advisory Panel; TIXiMED, Senseion, ERX. Funding National Institutes of Health (R01 DK031036)

Insulin-Like Growth Factor Signaling in Alzheimer's Disease: Pathophysiology and Therapeutic Strategies

Targeting Insulin Signaling for the Treatment of Alzheimer's Disease.

Deregulation of Brain Insulin Signaling in Alzheimer’s Disease

Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer’s disease

Insulin Signaling in Sporadic Alzheimer's Disease.

Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer's disease

Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway

The Role of Insulin Signaling in Hippocampal-Related Diseases: A Focus on Alzheimer's Disease

Role of the Insulin-like Growth Factor System in Neurodegenerative Disease

The Role of Insulin-like Growth Factor I in Mechanisms of Resilience and Vulnerability to Sporadic Alzheimer's Disease

The role of PI3K signaling pathway in Alzheimer's disease

Conquering Insulin Network Dysfunctions in Alzheimer's Disease: Where Are We Today?

Loss of insulin signaling in astrocytes exacerbates Alzheimer-like phenotypes in a 5xFAD mouse model

The PI3K/Akt signaling axis in Alzheimer’s disease: a valuable target to stimulate or suppress?

The interaction between insulin resistance and Alzheimer's disease: a review article

A Focus on Alzheimer's Disease

The autocrine regulation of insulin-like growth factor-1 in human brain of Alzheimer’s disease

219-OR: Loss of Insulin Signaling in Microglia Impairs Cellular Uptake of Aß and Neuroinflammatory Response Exacerbating Alzheimer-Like Neuropathology

Cerebral insulin, insulin signaling pathway, and brain angiogenesis

Insulin and Insulin Resistance in Alzheimer’s Disease

Epigenetic Alterations in Alzheimer's Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems